Finding advances search for cure other than liver transplantation
A protein modified to increase the amount of time it circulates in the bloodstream appears to reverse liver fibrosis and cirrhosis in rats, according to results of a study led by Johns Hopkins researchers.
The investigators say the findings, reported ahead of print in the March 3 early view edition of Hepatology, advance the search for a potential cure for the thousands of patients worldwide living with these incurable diseases. At present, there is little effective treatment and no cure other than liver transplantation, which carries its own risks and often fails.
“Our findings demonstrate that the damaging effects of liver cirrhosis in laboratory rats can be effectively treated, and perhaps even reversed, using a protein therapeutic that has been modified to enhance its activity through site-specific conjugation of a polymer that greatly enhances its residence time in the body,” says senior author Justin Hanes, Ph.D., director of the Center for Nanomedicine at the Wilmer Eye Institute at Johns Hopkins. “This approach has tremendous potential to help people with this devastating condition and may also be helpful to the millions of patients with other diseases where fibrosis plays an important role.”
Liver fibrosis and its more severe form, cirrhosis, are caused by scar tissue that forms in the liver that is usually induced by chronic alcohol abuse, infections and autoimmune diseases. The progressive stiffening of the liver, a hallmark of the disorders, occurs when a type of liver cell known as the hepatic stellate cell is “activated” and overproduces the stringy network of proteins called the extracellular matrix that binds cells together.
Being able to turn cirrhosis around, especially in its late stages, would be a great boon, says Seulki Lee, Ph.D., assistant professor in the Department of Radiology and Radiological Science at the Johns Hopkins University School of Medicine. “That’s because liver fibrosis and cirrhosis can be asymptomatic for decades,” Lee says. “Many patients only seek treatment when their disease becomes very advanced, at which point liver transplant is their only option.”
Lee cautions, however, that his team’s work is years from any possible application to patients.
Scientists have known for more than a decade that a protein called tumor necrosis factor-related apoptosis-inducing ligand — TRAIL, for short — can specifically kill activated hepatic stellate cells that overproduce the extracellular matrix, sparing healthy cells in the liver. However, Lee explains, TRAIL has thus far proven unsuccessful for clinical use because in animal studies, enzymes in the bloodstream quickly degrade it before it has time to work.
Seeking a way to extend TRAIL’s half-life, or the time that it remains intact in the bloodstream, Lee and his colleagues coated TRAIL with polyethylene glycol (PEG), a synthetic polymer that’s widely used as a preservative, lubricant and ingredient in skin creams, and is already being used to extend the bloodstream life of a handful of drugs that treat neutropenia, hemophilia and rheumatoid arthritis.
Lee says initial experiments showed that this “PEGylated” TRAIL had a half-life of between eight and nine hours in monkeys, compared to less than 30 minutes for the unmodified protein. When the scientists intravenously dosed rats that had liver fibrosis with the modified TRAIL for 10 days, the animals’ activated hepatic stellate cells died off. By fighting these bad cells, signs of fibrosis began to diminish. Further investigation showed that multiple genes associated with fibrosis had reduced activity, and the proteins produced by these genes faded away.
Findings were similar in rats with advanced cirrhosis, Lee says. Additionally, when the researchers examined the rodents’ liver tissue under a microscope, they found that animals treated with PEGylated TRAIL had fewer deposits of collagen and other extracellular matrix proteins, offering some evidence that the disease had actually been reversed.
Further experiments showed that PEGylated TRAIL selectively killed human-activated hepatic stellate cells growing in petri dishes while leaving normal liver cells unharmed, suggesting that findings in these animal models could apply to damaged human livers with limited toxicity concerns.
Lee says the research team hopes to develop PEGylated TRAIL for clinical trials in human patients in the next two years. He adds that some preliminary data suggest that the modified protein could also treat other fibrotic diseases as well, such as pancreatic or lung fibrosis, which also have no effective treatment.
“Eventually,” Lee says, “we might be able to develop PEGylated TRAIL into a universal anti-fibrotic agent that can treat many different conditions.”
Learn more: Modified protein reverses cirrhosis in lab rats
The Latest on: Protein therapeutic
[google_news title=”” keyword=”Protein therapeutic” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Protein therapeutic
- Researchers discover how a protein deficiency can prepare the brain to minimize damage after stresson February 3, 2023 at 4:25 pm
Astrocytes, small star-shaped cells, play an important role in signal transmission in the brain. Since the protein Ezrin is found abundantly in astrocyte tendrils, it is presumed to play a role in ...
- Diabetes drug developer Structure Therapeutics stock soars 72% in market debuton February 3, 2023 at 1:14 pm
Structure Therapeutics (GPCR) stock rallied 72% in afternoon trading Friday after the diabetes drug developer raised $161M through an upsized US initial public offering. Load Error American ...
- Structure Therapeutics’ IPO Raises $161M for Pills to Rival Blockbuster Biologicson February 3, 2023 at 12:08 pm
Despite challenging financial market conditions, clinical-stage Structure Therapeutics was able to upsize its IPO. Much of the new cash will support its lead program, an oral small molecule that could ...
- Feinstein Institutes researcher discovers potential therapeutic target for lethal sepsison February 3, 2023 at 11:20 am
The sepsis study, led by Haichao Wang, PhD, was recently published in the American Association for the Advancement of Science's journal, Science Advances Sepsis is a silent and mysterious killer that ...
- How the absence of a protein could help people better cope with the consequences of a strokeon February 3, 2023 at 7:22 am
Astrocytes are star-shaped cells in the brain that play an important role in maintaining the blood-brain barrier, supplying nerve cells with nutrients, and removing metabolic products. At more than 50 ...
- Plasma Protein Therapeutics Market 2023: Magnificent Analysis Report for Huge Growth with Forthcoming Challenges Forecast to 2027on February 3, 2023 at 3:35 am
“Plasma Protein Therapeutics Market” research providing information to drive merges and acquisition strategies to expand market Share, 2023-2027. Report also providing business strategy with different ...
- Plasma Protein Therapeutics Market Size 2023 With The Increasing Need To Extend Outlook 2027on February 2, 2023 at 5:44 pm
Plasma Protein Therapeutics Market 2023 with 123 Pages Report and enhance with extents shares into sub-counties are ...
- Peptide Therapeutics Market Size, Trends, Share and Forecast Report 2022-2027on February 2, 2023 at 1:35 pm
The global peptide therapeutics market reached a value of US$ 35.9 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 61.9 Billion by 2027, exhibiting a CAGR of 9.42% during ...
- AI and Computational Design Advance Protein Engineeringon February 2, 2023 at 7:59 am
With data-driven methods such as de novo protein design and iterative engineering, drug development is becoming more deliberate and systematic.
- Protein with anti-aging action combats inflammation and avoids death of neuronson February 1, 2023 at 10:12 am
The process of cellular aging is multifactorial, and its investigation involves several knowledge areas. Finding ways to protect cells against damage is a key focus.
via Bing News